Highlights 

  • Immix Biopharma reports encouraging Phase 2 data for NXC-201 in relapsed/refractory AL Amyloidosis at ASH 2025. 
  • NXC-201 achieved a 75% complete response rate, vastly exceeding typical outcomes in this patient population. 
  • MRD negativity suggests the complete response rate may rise to 95% as pending patients mature. 
  • Final NEXICART-2 readout and planned BLA submission are targeted for 2026. 
  • Safety profile shows no neurotoxicity and only brief low-grade CRS. 

Immix Biopharma (NASDAQ:IMMX) announced promising Phase 2 clinical results for its sterically optimized CAR-T candidate NXC-201 during an oral presentation at ASH 2025. Led by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, the data highlighted a 75% complete response rate in relapsed/refractory AL Amyloidosis patients who had previously been treated with an anti-CD38 antibody and a proteasome inhibitor. This outcome is noteworthy given that current treatment options typically deliver CR rates near 10% or below, underscoring the severity and treatment resistance of this disease setting. 

In addition, minimum residual disease negativity was identified in four out of five pending patients, signaling a likely future CR rate of up to 95% once all responses mature. This could significantly shift expectations for therapy effectiveness in this challenging indication. 

Safety, Clinical Improvements, and ASH Insights 

Beyond response rates, NXC-201 delivered encouraging safety results. Investigators observed no neurotoxicity across the evaluated patient pool. Instances of cytokine release syndrome remained low-grade, with a median duration of one day. Organ improvement was recorded in 70% of evaluable patients, further reinforcing the therapy’s clinical impact. 

All findings presented at ASH were based on data collected through November 13, 2025. Immix Biopharma will further discuss the implications of these results during a Key Opinion Leader event featuring leading experts from Cleveland Clinic, Boston Medical Center, and Memorial Sloan Kettering Cancer Center. 

Path Toward BLA Submission and Market Impact 

The Phase 2 outcomes were generated from NEXICART-2 (NCT06097832), a multi-site U.S. study designed with registrational intent. The trial aims to enroll 40 patients and will serve as the foundation for a potential BLA submission in 2026. Given the projected growth of the AL Amyloidosis population and the sizeable market—estimated at USD 3.6 billion in 2017 and expected to reach USD 6 billion by 2025—NXC-201 may become a transformative entrant if future data remain consistent. 

Immix Biopharma continues to position itself at the forefront of AL Amyloidosis innovation. With regulatory designations including RMAT and Orphan Drug status in both the U.S. and EU, NXC-201 has secured a pathway designed for efficient advancement toward potential approval. 

Conclusion 

Immix Biopharma’s new Phase 2 results showcase meaningful progress for NXC-201 and offer renewed hope for patients facing relapsed/refractory AL Amyloidosis. As the company advances toward final NEXICART-2 readout and a planned 2026 BLA submission, the therapy appears well-positioned to redefine expectations in this disease area.  

Immix Biopharmas’ shares closed at USD 5.56, marking a 14.88% increase from the prior session.